PerkinElmer
check quantity

HypoxiSense 680 Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11070
619.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense™ 680 fluorescent imaging agent detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors. Pairing HypoxiSense with optical fluorescent imaging technology allows you to image and quantitate tumor sub-regions undergoing hypoxia-related changes, non-invasively and in vivo.

HypoxiSense in vivo imaging reagent is ideally suited for detecting hypoxia-induced changes in CA IX expression during:

  • Imaging in vivo mouse and rat tumors
  • Assessing therapeutic efficacy in drug screening of tumor models
  • Fluorescence microscopy of disease tissues

For the first time, hypoxia can be measured non-invasively in living mice and rats, as well as in ex vivo tissue samples. It's the perfect solution for the in vivo hypoxia researcher.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name HypoxiSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Angiogenesis, Arthritis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Brochure

HypoxySense 680 (Product Sheet)

Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense detects the tumor cell surface expression of carbonic,anhydrase 9 (CA IX) protein, which increases in hypoxic regions,within many tumors, especially in cervical, colorectal, non-small,cell lung tumors. Pairing HypoxiSense with optical fluorescent,imaging technology allows you to image and quantitate tumor,sub-regions undergoing hypoxia-related changes, non-invasively,and in vivo.

PDF 546 KB

Flyer

Technical Note

HypoxiSense 680 (Protocol)

HypoxiSense 680 in vivo imaging Protocol

PDF 257 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB